All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual Abstract | Prevalence and risk of SARS-CoV-2 infection in individuals with psoriasis: PsoCOVID cohort study
By Ella Dixon
Bookmark this article
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing data from the PsoCOVID study, which evaluated the risk and prevalence of SARS-CoV-2 infection in patients with psoriasis.1 Patients were evaluated based on whether they had received biologic therapy, non-biologic systemic therapy, or topical therapy, between March 2020– October 2021.1 Eligible patients completed a questionnaire and were tested for antibodies to SARS-CoV-2.1 Patient characteristics identified in the survey are shown in Table 1.
Table 1. Patient characteristics*
|
Characteristic, % (unless otherwise stated) |
N = 551 |
|---|---|
|
Sex, male |
56.1 |
|
Median age at study inclusion, years (range) |
59 (18–88) |
|
Median disease duration at study inclusion, years (range) |
25 (0.5–67) |
|
Psoriatic arthritis |
16.0 |
|
Treatment |
|
|
Topical therapy |
26.7 |
|
Biologic immunosuppressive therapy |
41.0 |
|
Systemic immunosuppressive therapy without biologic |
32.3 |
|
*Adapted from Kwee, et al.1 |
|
Of all 551 patients included in the study, 10.7% (59 patients) had experienced an infection with SARS-CoV-2 since the start of the pandemic.1 The PsoCOVID study suggests that there may be a lower risk for SARS-CoV-2 infection in patients treated with biologic therapy compared with systemic or topical therapies (odds ratio, 0.382, p = 0.011).1
- Kwee KV, Murk J-L, Yin Q, et al. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a crosssectional cohort study (PsoCOVID). J Dermatolog Treat. 2023; 34(1):2161297. DOI: 1080/09546634.2022.2161297
More about...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox